Invite a paper's author to join your next session.

The group reviewed ORBITA-CTO, agreeing that its sham-controlled design conclusively proves CTO PCI reduces angina frequency beyond placebo at 24 weeks. Clinicians emphasized that the trial supports a more selective, symptom-driven approach rather than expanding procedural volume. Key limitations discussed include the lack of clear benefit for dyspnea-predominant symptoms, the exclusion of J-CTO 4–5 lesions, and the absence of long-term durability data beyond six months.
Key takeaway: ORBITA-CTO confirms that CTO PCI reduces angina frequency beyond placebo at 24 weeks, supporting more selective rather than broad procedural use.
With David J. Cohen and 16 experts
Find your room
Continue the conversation
Where leading experts discuss new research and decide what matters.
Explore Journal Clubs